It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $3.3 billion, an increase of 10% compared to Q4 2023, with diagnostics and biopharma revenue each growing by approximately 10% [13][28] - Adjusted EPS for the quarter was $3.45, up 5% year-over-year [14][31] - Free cash flow from continuing operations was $665 million for the quarter [32] Business Line Data and Key Metrics Changes - Diagnostics revenue for the quarter was $2.6 billion, an increase of 10.2% compared to last year, driven by organic growth of 5.1% and net acquisitions of 5.2% [36] - Biopharma Laboratory Services revenue for the quarter was $767 million, an increase of 10.4% compared to last year, with organic revenue growth of 8.9% [39] Market Data and Key Metrics Changes - The company expects enterprise revenue growth of 6.7% to 8% for 2025, with diagnostics revenue projected to grow by 6.5% to 7.7% [15][43] - Biopharma revenue is expected to grow by 3% to 5% compared to 2024 [44] Company Strategy and Development Direction - The company advanced its leadership position through 10 acquisitions in 2024, focusing on high-growth markets such as oncology, women's health, neurology, and autoimmune disease [9][10] - The company aims to support health systems and expand access to diagnostic solutions while continuing to innovate in science and technology [18][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in margin expansion for both diagnostics and biopharma, despite initial dilution from the Invitae acquisition [52][127] - The company anticipates a strong growth profile, with adjusted EPS growth expected in the range of 10% for 2025 [15][68] Other Important Information - The company has a robust pipeline of potential acquisition opportunities and plans to utilize free cash flow for acquisitions, share repurchases, and dividends [34][65] - The company ended 2024 with $1.5 billion in cash and total debt of $6.3 billion, with a debt leverage ratio of 2.2 times [35] Q&A Session Summary Question: Can you give us a sense of what underlying margins are in terms of embedded into guidance? - Management indicated that diagnostics margins were impacted by Invitae, weather, and days, but they expect margin expansion in 2025 due to anticipated growth and operational improvements [51][52] Question: How do you see the environment going forward for diagnostics? - Management expects a balanced growth profile for diagnostics, with half of the growth coming from organic sources and the other half from acquisitions [57][122] Question: Can you provide an update on your acquisition pipeline? - Management expressed confidence in a strong acquisition pipeline, emphasizing a balanced approach to capital allocation, including dividends and share repurchases [60][62] Question: How is the integration of Invitae progressing? - Management reported that the integration is going well, with expectations for revenue growth of more than 10% and slight accretion in the second half of 2025 [72][73] Question: What are the expectations for organic growth in diagnostics? - Management highlighted that esoteric testing in specific areas is growing at three times the typical rate, contributing to overall organic growth expectations [78][80]

Core Insights - Laboratory Corp reported fourth-quarter 2024 adjusted earnings per share of $3.45, an increase from $3.30 a year ago, surpassing the consensus estimate of $3.39 [1] - Sales rose 9.8% year-over-year to $3.33 billion, nearly matching the consensus of $3.31 billion, driven by organic revenue growth of 5.4%, acquisitions net of divestitures of 4%, and foreign currency translation of 0.3% [1] - Adjusted operating income for the quarter was $423.2 million, or 12.7% of revenue, compared to $394.9 million, or 13%, in the same quarter last year [2] Company Performance - The company experienced exceptional results in 2024, attributed to both organic and inorganic growth, with a focus on high-growth areas such as oncology, women's health, neurology, and autoimmune disease [2] - The diagnostics segment is benefiting from favorable macro tailwinds, while the Biopharma Laboratory Services segment is seeing solid growth in central labs [3] Future Guidance - LabCorp expects adjusted EPS for 2025 to be between $15.60 and $16.40, compared to the consensus of $16.0, and anticipates sales of $13.9 billion to $14.1 billion against a consensus of $13.8 billion [4] - The guidance includes expected sales growth of 6.5% to 7.7% for Diagnostics Laboratories and 3.0% to 5.0% for Biopharma Laboratory Services in 2025 [4] Market Reaction - Laboratory Corp's stock was down 0.92% at $247.68 during the last check on Thursday [4]

Labcorp (LH) reported $3.33 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 9.8%. EPS of $3.45 for the same period compares to $3.30 a year ago.The reported revenue represents a surprise of +0.44% over the Zacks Consensus Estimate of $3.32 billion. With the consensus EPS estimate being $3.40, the EPS surprise was +1.47%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expe ...

Core Viewpoint - Labcorp Holdings reported better-than-expected earnings and revenues for the fourth quarter of 2024, showcasing strong organic and inorganic growth, although margins contracted [11][12]. Financial Performance - Adjusted EPS for Q4 2024 was $3.45, a 4.5% increase year-over-year, beating the Zacks Consensus Estimate by 1.5% [1][2]. - GAAP EPS for Q4 was $1.70, compared to a loss of $1.95 in the same period last year [2]. - Total revenues for Q4 rose 9.8% year-over-year to $3.33 billion, surpassing the Zacks Consensus Estimate by 0.6% [3][4]. - For the full year, adjusted EPS was $14.57, up 7.4% from the previous year, and also exceeded the Zacks Consensus Estimate by 0.4% [2][4]. Revenue Breakdown - Diagnostics Laboratories segment reported revenues of $2.59 billion, reflecting a 10.2% year-over-year improvement [5]. - Biopharma Laboratory Services revenues increased by 10.4% to $767 million, driven by organic growth of 8.9% [6]. - Organic revenues for the quarter were up 5.4%, with a 6.2% rise in the Base Business, partially offset by a 0.8% decline in COVID-19 testing [3][6]. Margin Analysis - Gross margin contracted by 16 basis points to 26.9% due to a 9.1% rise in the cost of revenues [7]. - Adjusted operating income improved by 4.4% year-over-year to $301.1 million, but the adjusted operating margin contracted by 47 basis points to 9% [7]. Cash Position - Labcorp ended Q4 with cash and cash equivalents of $1.52 billion, significantly up from $536.8 million at the end of 2023 [8]. - Long-term debt totaled $5.33 billion, a 31.5% increase from the previous quarter [8]. - Cumulative cash inflow from operating activities was $1.59 billion, compared to $1.20 billion at the end of 2023 [8]. Future Guidance - Total revenues for 2025 are expected to grow between 6.7% and 8%, with Diagnostics Laboratories revenues projected to increase by 6.5% to 7.7% [9]. - Full-year adjusted EPS for 2025 is expected to be in the range of $14.57 to $15.60, with the Zacks Consensus Estimate at $15.97 [9]. Strategic Developments - Labcorp is enhancing its Global Trial Connect to speed up clinical trials and expanding its Labcorp OnDemand test menu [11][12]. - The company introduced a companion diagnostic assay for gastric cancer patients, marking a significant advancement in targeted treatment [12].

Core Viewpoint - Labcorp reported quarterly earnings of $3.45 per share, exceeding the Zacks Consensus Estimate of $3.40 per share, and showing an increase from $3.30 per share a year ago, indicating a positive earnings surprise of 1.47% [1] Financial Performance - Labcorp's revenues for the quarter ended December 2024 were $3.33 billion, surpassing the Zacks Consensus Estimate by 0.44%, and up from $3.03 billion year-over-year [2] - The company has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - Labcorp shares have increased approximately 9% since the beginning of the year, compared to a 3.1% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $3.90 on revenues of $3.42 billion, and for the current fiscal year, it is $15.97 on revenues of $13.84 billion [7] - The trend of estimate revisions for Labcorp has been favorable leading up to the earnings release [6] Industry Context - The Medical - Dental Supplies industry, to which Labcorp belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may impact stock performance [8]

FOR IMMEDIATE RELEASE Media Investors Media@Labcorp.com Investor@labcorp.com Labcorp Announces 2024 Fourth Quarter and Full Year Results Company Provides 2025 Guidance BURLINGTON, N.C., February 6, 2025 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter ended December 31, 2024, and provided 2025 guidance. "In 2024, Labcorp delivered exceptional results driven by both organic and inorganic growth," said Adam ...

Company Provides 2025 Guidance Results from Continuing Operations versus last year: Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billion Diluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs $4.33 Adjusted EPS: Q4 of $3.45 vs $3.30; Full year of $14.57 vs $13.56 Free Cash Flow: Q4 of $665.1 million vs $412.4 million; Full year of $1.10 billion vs $748.7 million Announced 10 transactions and launched new innovative tests meeting significant unmet medical needs ...

The upcoming report from Labcorp (LH) is expected to reveal quarterly earnings of $3.40 per share, indicating an increase of 3% compared to the year-ago period. Analysts forecast revenues of $3.31 billion, representing an increase of 9.3% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is cruc ...

Labcorp Holdings Inc. (LH) , or Labcorp, is slated to report its fourth-quarter 2024 results on Feb. 6 before the opening bell.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The renowned laboratory service provider reported adjusted earnings of $3.50 in the last reported quarter, topping the Zacks Consensus Estimate by 0.56%. Labcorp surpassed estimates in each of the trailing four quarters, the average surprise being 2.87%.LH’s Q4 EstimatesThe Zacks Consensus Estimate for Labcorp’s ...